Despite the number of times a number of posters on a number of threads have repeatedly explained that Remdesivir is an anti-viral (prevents viral replication) and Rememstemcel-L is not an anti-viral but treats the consequences of Covid-ARDS and pneumonia@whytee still comes back with "Well they are competing, but its impossible to judge how successfully unless there is a head to head controlled trial, which probably both companies would not want..."
A head to head controlled trial of these two products is an impossibility. An absurdity. They are not competing. They cannot compete. Be like having a head to head trial of aspirin vs penicillin. To do what?
Just one of the explanatory posts I refer to is one of mine from just yesterday, Post #:44092864 I put this link here to save me going through it all again.
I'm fairly sure most posters understand this and find it repetitive. In fact I'd be surprised if whytee doesn't understand it also and I wonder why he tries to sow confusion.
MSB Price at posting:
$2.17 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)